These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9203945)

  • 1. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.
    Suwa H; Ohshio G; Okada N; Wang Z; Fukumoto M; Imamura T; Imamura M
    Gut; 1997 May; 40(5):647-53. PubMed ID: 9203945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEACAM1, a novel serum biomarker for pancreatic cancer.
    Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
    Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumor markers not useful in screening patients with pancreatic mucinous cystic lesions associated with malignant changes.
    Pezzilli R; Calculli L; Melzi d'Eril G; Barassi A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):553-557. PubMed ID: 27733327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.
    Hammel P; Boissier B; Chaumette MT; Piedbois P; Rotman N; Kouyoumdjian JC; Lubin R; Delchier JC; Soussi T
    Gut; 1997 Mar; 40(3):356-61. PubMed ID: 9135525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
    Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
    J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
    Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
    Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
    Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
    Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M; Gerstlauer C; Grimm M; Bueter M; Lebedeva T; Lutz J; Maeder U; Ribas C; Ribas C; Nichiporuk E; Thalheimer A; Heemann U; Thiede A; Meyer D; Waaga-Gasser AM
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.
    Tanase CP; Dima S; Mihai M; Raducan E; Nicolescu MI; Albulescu L; Voiculescu B; Dumitrascu T; Cruceru LM; Leabu M; Popescu I; Hinescu ME
    J Mol Histol; 2009 Feb; 40(1):23-9. PubMed ID: 19160064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
    Koopmann J; Buckhaults P; Brown DA; Zahurak ML; Sato N; Fukushima N; Sokoll LJ; Chan DW; Yeo CJ; Hruban RH; Breit SN; Kinzler KW; Vogelstein B; Goggins M
    Clin Cancer Res; 2004 Apr; 10(7):2386-92. PubMed ID: 15073115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
    Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
    Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
    Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
    J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
    Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
    J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 and follow-up of colorectal adenocarcinomas.
    Polge A; Bourgaux JF; Bancel E; Pignodel C; Boyer JC; Poirey S; de Bornier BM; Balmes JL; Bali JP
    Dig Dis Sci; 1998 Jul; 43(7):1434-42. PubMed ID: 9690377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of preoperative serum anti-p53 antibodies in gastric cancer.
    Nakajima K; Suzuki T; Shimada H; Hayashi H; Takeda A; Ochiai T
    Tumour Biol; 1999; 20(3):147-52. PubMed ID: 10213922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
    Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
    Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.